All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
How I treat” a patient with lower-risk MDS showing signs of ESA failure
Theo de Witte discusses the optimal timing of erythropoiesis-stimulating agent (ESA) treatment in patients with lower-risk MDS and how to optimize treatment following ESA-treatment failure, including the use of luspatercept; he highlights results from the phase III MEDALIST (NCT02631070) and COMMANDS (NCT03682536) trials. The committee also discusses the assessment of quality of life in placebo-controlled studies and the use of luspatercept as a first-line therapy over ESAs, specifically in patients with MDS and SF3B1 mutations. They also raise the need to consider the side effects of luspatercept and the cost of treatment.
Luspatercept for ESA-naïve TD patients with LR-MDS: Interim analysis from the COMMANDS study
Here, we summarize an interim analysis from the COMMANDS trial recently published by Platzbecker, et al. in The Lancet, as well as presentations by Guillermo...
Luspatercept reduces red blood cell transfusion burden on patients with very low to intermediate risk MDS without negative impact on health-related quality of life
Myelodysplastic syndromes (MDS) are a heterogenous group of clonal hematopoietic...
Will luspatercept become the new treatment standard after ESA failure in RS-positive LR-MDS patients with TD anemia?
Erythropoiesis-stimulating agents (ESAs) are the standard first-line treatment for low-risk anemic patients with myelodysplastic...
Subscribe to get the best content related to MDS delivered to your inbox